Drug Target Review – Issue #2 2017
Posted: 2 June 2017 | Drug Target Review | No comments yet
Included in this issue: Technology convergence improves testing; Screening; Stem Cells; Targets; Mass Spectrometry; and Therapeutics in Alzheimer’s disease…
- Foreword: Technology convergence improves testing models
Anton Simeonov, Scientific Director of the Division of Pre-Clinical Innovation (DPR) at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health - In-Depth Focus: Screening
- Genomics: Review: biomarkers towards personalised therapy in cancer
Mahvash Tavassoli and Katheryn Begg, King’s College London - In-Depth Focus: Stem Cells
- Mass Spectrometry: Using native mass spectrometry to inform drug discovery
Idlir Liko, OMass Technologies and University of Oxford; Timothy M Allison, OMass Technologies and University of Oxford; Hsin-Yung Yen, OMass Technologies and University of Oxford; Jonathan S.T. Hopper, OMass Technologies; Carol V. Robinson, OMass Technologies and University of Oxford - In-Depth Focus: Targets
- Research area: CNS: Insights from discovery through clinical efficacy to support a new class of therapeutics in Alzheimer’s disease
Petr Kocis, John A Hey, Susan Abushakra, Aidan Power, and Martin Tolar, Alzheon
The digital version of Issue #2 2017 is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related topics
Biomarkers, Drug Development, Drug Discovery, Drug Targets, Mass Spectrometry, Oncology, Screening, Stem Cells, Therapeutics